Literature DB >> 15914535

Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial.

Eleftherios P Paschalis1, Emmett V Glass, David W Donley, Erik F Eriksen.   

Abstract

CONTEXT: Evidence suggests that both bone mineral density and bone quality should be taken into account when assessing bone strength and fracture risk. Bone quality is a multifactor entity, of which bone architecture and material properties are two important components. Matrix mineralization, hydroxyapatite characteristics, and collagen cross-link ratio are key determinants of material properties. Fourier transform infrared imaging (FTIRI) yields data on these characteristics from bone sections.
OBJECTIVE: We sought to determine collagen cross-link ratios and matrix mineralization of bone from patients randomized to teriparatide [recombinant human PTH (1-34)] treatment using FTIRI.
DESIGN: The Fracture Prevention Trial was randomized, double blind, and placebo-controlled.
SETTING: The trial was conducted at global clinical research centers. PATIENTS: Patients consisted of postmenopausal women with osteoporosis.
INTERVENTIONS: Patients were randomized to receive daily sc injections of placebo (n = 12) or 20 microg (n = 13) or 40 microg (n = 13) teriparatide. Biopsies were obtained after 12 months of treatment or at the end of treatment (range, 19-24 months for end of treatment paired biopsies). MAIN OUTCOME MEASURES: Biopsies were analyzed by FTIRI to determine the matrix mineralization (mineral to matrix), mineral crystallinity, and collagen cross-link ratio (pyridinoline/dehydrodihydroxylysinonorleucine) with a spatial resolution of approximately 6.3 microm.
RESULTS: Patients administered teriparatide 20 and 40 microg/d exhibited significantly lower matrix mineralization, mineral crystallinity, and collagen cross-link ratio when compared with placebo.
CONCLUSIONS: These findings indicate that the bone-forming effect of teriparatide results in bone with a molecular profile reminiscent of younger bone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914535     DOI: 10.1210/jc.2004-2489

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

1.  Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis.

Authors:  Maria-Grazia Ascenzi; Vivian P Liao; Brittany M Lee; Fabrizio Billi; Hua Zhou; Robert Lindsay; Felicia Cosman; Jeri Nieves; John P Bilezikian; David W Dempster
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

2.  Hydroxyapatite-collagen composites. Part I: can the decrease of the interactions between the two components be a physicochemical component of osteoporosis in aged bone?

Authors:  Niccoletta Barbani; Elisabetta Rosellini; Caterina Cristallini; Giulio D Guerra; Adriano Krajewski; Mauro Mazzocchi
Journal:  J Mater Sci Mater Med       Date:  2011-01-30       Impact factor: 3.896

Review 3.  Infrared assessment of bone quality: a review.

Authors:  Eleftherios P Paschalis; Richard Mendelsohn; Adele L Boskey
Journal:  Clin Orthop Relat Res       Date:  2011-08       Impact factor: 4.176

4.  Bone material properties in premenopausal women with idiopathic osteoporosis.

Authors:  Barbara M Misof; Sonja Gamsjaeger; Adi Cohen; Birgit Hofstetter; Paul Roschger; Emily Stein; Thomas L Nickolas; Halley F Rogers; David Dempster; Hua Zhou; Robert Recker; Joan Lappe; Donald McMahon; Eleftherios P Paschalis; Peter Fratzl; Elizabeth Shane; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

5.  Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study.

Authors:  B M Misof; P Roschger; S Blouin; R Recker; K Klaushofer
Journal:  Osteoporos Int       Date:  2015-12-09       Impact factor: 4.507

6.  Studying variations in bone composition at nano-scale resolution: a preliminary report.

Authors:  Samuel Gourion-Arsiquaud; Curtis Marcott; Qichi Hu; Adele L Boskey
Journal:  Calcif Tissue Int       Date:  2014-08-26       Impact factor: 4.333

Review 7.  Assessment of bone mineral and matrix using backscatter electron imaging and FTIR imaging.

Authors:  Adele L Boskey
Journal:  Curr Osteoporos Rep       Date:  2006-06       Impact factor: 5.096

Review 8.  Investigation of bone with synchrotron radiation imaging: from micro to nano.

Authors:  F Peyrin
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

9.  Effects of bone anabolic agents on bone ultrastructure.

Authors:  B Cortet
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

10.  Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Authors:  R A Wermers; C P Recknor; F Cosman; L Xie; E V Glass; J H Krege
Journal:  Osteoporos Int       Date:  2008-02-19       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.